Olivier Michielin

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil

210 publications

In press | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | ...
A phase 1, open-label study of pasireotide in patients with BRAF- and NRAS wild type, unresectable, and/or metastatic melanoma
Dummer R., Michielin O.A., Nägeli M., Goldinger S.M., Campigotto F., Kriemler-Krahn U., Schmid H., Pedroncelli A., Micaletto S., Schadendorf D. ESMO Open.
Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.
Frisone D., Charrier M., Clement S., Christinat Y., Thouvenin L., Homicsko K., Michielin O., Bodmer A., Chappuis P.O., McKee T.A. et al. Cancer biology & therapy pp. 1-6. Peer-reviewed.
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Middleton M.R., Hoeller C., Michielin O., Robert C., Caramella C., Öhrling K., Hauschild A. British journal of cancer. Peer-reviewed.
Prise en charge par l’ORL des mélanomes cutanés cervico-faciaux [ENT management of head and neck cutaneous melanoma]
Jaballah Vinckenbosch P., Litzistorf Y., Gaide O., Özdemir B.C., Michielin O., Reinhard A., 2020/10/07. Revue medicale suisse, 16 (709) pp. 1853-1859. Peer-reviewed.
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.
Curigliano G., Banerjee S., Cervantes A., Garassino M.C., Garrido P., Girard N., Haanen J., Jordan K., Lordick F., Machiels J.P. et al., 2020/10. Annals of oncology, 31 (10) pp. 1320-1335. Peer-reviewed.
What Role Can Process Mining Play in Recurrent Clinical Guidelines Issues? A Position Paper.
Gatta R., Vallati M., Fernandez-Llatas C., Martinez-Millana A., Orini S., Sacchi L., Lenkowicz J., Marcos M., Munoz-Gama J., Cuendet M.A. et al., 2020/09/11. International journal of environmental research and public health, 17 (18) pp. E6616. Peer-reviewed.
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A., Hottinger A., Wolf B., Navarro Rodrigo B., Ochoa de Olza M., Auger A., Kuntzer T., Comte D., Zimmer V., Gannon P. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e001155. Peer-reviewed.
ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee.
Michielin O., van Akkooi A., Lorigan P., Ascierto P.A., Dummer R., Robert C., Arance A., Blank C.U., Sileni V.C., Donia M. et al., 2020/07/22. Annals of oncology. Peer-reviewed.
ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee.
Keilholz U., Ascierto P.A., Dummer R., Robert C., Lorigan P., van Akkooi A., Arance A., Blank C.U., Sileni V.C., Donia M. et al., 2020/07/22. Annals of oncology. Peer-reviewed.
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C. et al., 2020/07. The Lancet. Oncology, 21 (7) pp. 914-922. Peer-reviewed.
SPHN/PHRT - MedCo in Action: Empowering the Swiss Molecular Tumor Board with Privacy-Preserving and Real-Time Patient Discovery.
Raisaro J.L., Troncoso-Pastoriza J.R., Pradervand S., Cuendet M., Misbach M., Sa J., Marino F., Freundler N., Rosat N., Cavin D. et al., 2020/06/16. Studies in health technology and informatics, 270 pp. 1161-1162. Peer-reviewed.
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.
Whisenant J.G., Trama A., Torri V., De Toma A., Viscardi G., Cortellini A., Michielin O., Barlesi F., Dingemans A.C., Van Meerbeeck J. et al., 2020/06/08. Cancer cell, 37 (6) pp. 742-745. Peer-reviewed.
Cardiotoxicité des inhibiteurs de points de contrôle immunitaire utilisés dans le traitement des cancers [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]
Arangalage D., Pavon A.G., Hugelshofer S., Desgraz B., Tzimas G., Delyon J., Muller O., Obeid M., Ribi C., Michielin O. et al., 2020/06/03. Revue medicale suisse, 16 (696) pp. 1165-1168. Peer-reviewed.
Mélanome localement avancé et métastatique : nouveautés [Locally advanced and metastatic melanoma : novelties]
Huber A., Latifyan S., Nikolopoulou A., Homicsko K., Berthod G., Michielin O., Özdemir B.C., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1092-1097. Peer-reviewed.
Oncologie : naviguer la pandémie de COVID-19 et garder le cap [Oncology: navigating the COVID-19 Pandemic and Steer the Course]
Zimmermann S., Dietrich P.Y., Michielin O., Betticher D., Peters S., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) pp. 819-822. Peer-reviewed.
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.
Ascierto P.A., Agarwala S.S., Eggermont A., Gershenwald J.E., Grob J.J., Hamid O., Michielin O., Postow M., Puzanov I., Zarour H.M. et al., 2020/04/16. Journal of translational medicine, 18 (1) p. 171. Peer-reviewed.
First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver.
Ponti A., Denys A., Digklia A., Schaefer N., Hocquelet A., Knebel J.F., Michielin O., Dromain C., Duran R., 2020/03. Journal of nuclear medicine, 61 (3) pp. 350-356. Peer-reviewed.
Integrating radiomics into holomics for personalised oncology: from algorithms to bedside.
Gatta R., Depeursinge A., Ratib O., Michielin O., Leimgruber A., 2020/02/07. European radiology experimental, 4 (1) p. 11. Peer-reviewed.
Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M., Kuncewicz K., Sieradzan A., Karczyńska A., Iwaszkiewicz J., Cesson V., Węgrzyn K., Zhukov I., Maszota-Zieleniak M., Michielin O. et al., 2020/01/18. International journal of molecular sciences, 21 (2). Peer-reviewed.
Oncologie [Advances in Oncology 2019]
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V. et al., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 72-77. Peer-reviewed.
The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F., Schiappacasse L., Levivier M., Tuleasca C., Cuendet M.A., Aedo-Lopez V., Gautron Moura B., Homicsko K., Bettini A., Berthod G. et al., 2020/01. Journal of neuro-oncology, 146 (1) pp. 181-193. Peer-reviewed.
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V., Dunet V., Hottinger A.F., Berthod G., Schiappacasse L., Peters S., Michielin O., Aedo-Lopez V., 2019/12/02. Journal for immunotherapy of cancer, 7 (1) p. 336. Peer-reviewed.
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Michielin O., van Akkooi ACJ, Ascierto P.A., Dummer R., Keilholz U., ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, 2019/12/01. Annals of oncology, 30 (12) pp. 1884-1901. Peer-reviewed.
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U., Michielin O., Lluesma S.M., Tsourti Z., Polydoropoulou V., Karlis D., Besser M.J., Haanen J., Svane I.M., Ohashi P.S. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1902-1913. Peer-reviewed.
Herpes simplex encephalitis in adult patients with MASP-2 deficiency.
Bibert S., Piret J., Quinodoz M., Collinet E., Zoete V., Michielin O., Menasria R., Meylan P., Bihl T., Erard V. et al., 2019/12. PLoS pathogens, 15 (12) pp. e1008168. Peer-reviewed.
The Romand Network of Oncology: bridging the gap of personalised oncology
Michielin O., Tsantoulis P., Homicsko K., Christinat Y., De Leval L., Bisig B., Missiaglia E., Zoete V., Krebs F., Fortin A. et al., 2019/10/18. Swiss Medical Weekly.
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y. et al., 2019/09. Nature reviews. Clinical oncology, 16 (9) pp. 563-580. Peer-reviewed.
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).
Ascierto P.A., Agarwala S.S., Botti G., Budillon A., Davies M.A., Dummer R., Ernstoff M., Ferrone S., Formenti S., Gajewski T.F. et al., 2019/07/22. Journal of translational medicine, 17 (1) p. 234. Peer-reviewed.
SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules.
Daina A., Michielin O., Zoete V., 2019/07/02. Nucleic acids research, 47 (W1) pp. W357-W364. Peer-reviewed.
Oncologie [Oncology, what's new in 2018]
Latifyan S., Kakourou A., Ozdemir B., Zaman K., Vernadou A., Berthold D., Abdelhamid K., Bouchaab H., Peters S., Montemurro M. et al., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 78-81. Peer-reviewed.
La médecine personnalisée en oncologie dans: Médecine Personnalisée
Colomer-Lahiguera S., Coukos G., Peters S., Kandalaft L., Michielin O., Eicher M., 2019. dans Médecine Personnalisée, Académie Suisse de Sciences Médicales.
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F., Sykiotis G.P., Maillard M., Fraga M., Ribi C., Kuntzer T., Michielin O., Peters S., Coukos G., Spertini F. et al., 2019/01. The Lancet. Oncology, 20 (1) pp. e54-e64. Peer-reviewed.
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
Ghosn J., Vicino A., Michielin O., Coukos G., Kuntzer T., Obeid M., 2018/10/22. Journal for immunotherapy of cancer, 6 (1) p. 110. Peer-reviewed.
CD73 expression and clinical significance in human metastatic melanoma.
Monteiro I., Vigano S., Faouzi M., Treilleux I., Michielin O., Ménétrier-Caux C., Caux C., Romero P., de Leval L., 2018/06/01. Oncotarget, 9 (42) pp. 26659-26669. Peer-reviewed.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
Redelman-Sidi G., Michielin O., Cervera C., Ribi C., Aguado J.M., Fernández-Ruiz M., Manuel O., 2018/06. Clinical microbiology and infection, 24 Suppl 2 pp. S95-S107. Peer-reviewed.
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Battistello E., Katanayeva N., Dheilly E., Tavernari D., Donaldson M.C., Bonsignore L., Thome M., Christie A.L., Murakami M.A., Michielin O. et al., 2018/05/24. Blood, 131 (21) pp. 2345-2356. Peer-reviewed.
Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy.
Kudchadkar R.R., Michielin O., van Akkooi ACJ, 2018/05/23. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 38 pp. 759-762. Peer-reviewed.
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1083 pp. 124-136. Peer-reviewed.
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi Janos L., Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J., Iseli Christian, Dangaj Denarda et al., 2018/04/11. Science Translational Medicine, 10 (436) pp. eaao5931.
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi J.L., Bobisse S., Ophir E., Tuyaerts S., Roberti A., Genolet R., Baumgartner P., Stevenson B.J., Iseli C., Dangaj D. et al., 2018/04/11. Science translational medicine, 10 (436) pp. NA. Peer-reviewed.
Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.
Tétu P., Mangana J., Dummer R., Dutriaux C., Beneton N., Dalle S., Meyer N., Oriano B., Michielin O., Lebbe C., 2018/04. European journal of cancer, 93 pp. 147-149. Peer-reviewed.
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S., Genolet R., Roberti A., Tanyi J.L., Racle J., Stevenson B.J., Iseli C., Michel A., Le Bitoux M.A., Guillaume P. et al., 2018/03/15. Nature communications, 9 (1) p. 1092. Peer-reviewed.
Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
Voruz S., Martins F., Cairoli A., Naveiras O., Homicsko K., Missiaglia E., de Leval L., Bisig B., Michielin O., Blum S., 2018/03. Haematologica, 103 (3) pp. e130. Peer-reviewed.
ECCO essential requirements for quality cancer care: Melanoma.
Wouters M.W., Michielin O., Bastiaannet E., Beishon M., Catalano O., Del Marmol V., Delgado-Bolton R., Dendale R., Trill M.D., Ferrari A. et al., 2018/02. Critical reviews in oncology/hematology, 122 pp. 164-178. Peer-reviewed.
T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus.
Bovay A., Zoete V., Dolton G., Bulek A.M., Cole D.K., Rizkallah P.J., Fuller A., Beck K., Michielin O., Speiser D.E. et al., 2018/02. European journal of immunology, 48 (2) pp. 258-272. Peer-reviewed.
Lymphatic vessel density is associated with CD8<sup>+</sup> T cell infiltration and immunosuppressive factors in human melanoma.
Bordry N., Broggi MAS, de Jonge K., Schaeuble K., Gannon P.O., Foukas P.G., Danenberg E., Romano E., Baumgaertner P., Fankhauser M. et al., 2018. Oncoimmunology, 7 (8) pp. e1462878. Peer-reviewed.
Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma.
Dummer R., Michielin O., Nägeli M.C., M Goldinger S., Campigotto F., Kriemler-Krahn U., Schmid H., Pedroncelli A., Micaletto S., Schadendorf D., 2018. ESMO open, 3 (5) pp. e000388. Peer-reviewed.
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Voruz S., Cairoli A., Naveiras O., de Leval L., Missiaglia E., Homicsko K., Michielin O., Blum S., 2018/01. Haematologica, 103 (1) pp. e39-e41. Peer-reviewed.
Mutant <i>CTNNB1</i> and histological heterogeneity define metabolic subtypes of hepatoblastoma.
Crippa S., Ancey P.B., Vazquez J., Angelino P., Rougemont A.L., Guettier C., Zoete V., Delorenzi M., Michielin O., Meylan E., 2017/11. EMBO molecular medicine, 9 (11) pp. 1589-1604. Peer-reviewed.
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.
Fankhauser M., Broggi MAS, Potin L., Bordry N., Jeanbart L., Lund A.W., Da Costa E., Hauert S., Rincon-Restrepo M., Tremblay C. et al., 2017/09/13. Science translational medicine, 9 (407) pp. 1-13. Peer-reviewed.
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Mangana J., Cheng P.F., Kaufmann C., Amann V.C., Frauchiger A.L., Stögner V., Held U., von Moos R., Michielin O., Braun R.P. et al., 2017/08. Melanoma research, 27 (4) pp. 358-368. Peer-reviewed.
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Dummer R., Hoeller C., Gruter I.P., Michielin O., 2017/06. Cancer immunology, immunotherapy : CII, 66 (6) pp. 683-695. Peer-reviewed.
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.
Daina A., Michielin O., Zoete V., 2017/03/03. Scientific reports, 7 p. 42717. Peer-reviewed.
A practical guide to the handling and administration of talimogene laherparepvec in Europe.
Harrington K.J., Michielin O., Malvehy J., Pezzani Grüter I., Grove L., Frauchiger A.L., Dummer R., 2017. OncoTargets and therapy, 10 pp. 3867-3880. Peer-reviewed.
Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M., Lach S., Iwaszkiewicz J., Cesson V., Kalejta K., Olive D., Michielin O., Speiser D.E., Zoete V., Derré L. et al., 2017. PloS one, 12 (6) pp. e0179201.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Ribas A., Dummer R., Puzanov I., VanderWalde A., Andtbacka RHI, Michielin O., Olszanski A.J., Malvehy J., Cebon J., Fernandez E. et al., 2017. Cell, 170 (6) pp. 1109-1119.e10. Peer-reviewed.
The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig U.F., Zoete V., Michielin O., 2017. Biochemistry, 56 (33) pp. 4323-4325. Peer-reviewed.
The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β2-Microglobulin through Distinct Binding Sites.
Merkle P.S., Irving M., Hongjian S., Ferber M., Jørgensen TJD, Scholten K., Luescher I., Coukos G., Zoete V., Cuendet M.A. et al., 2017. Biochemistry, 56 (30) pp. 3945-3961. Peer-reviewed.
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope
Baumgaertner P., Costa Nunes C., Cachot A., Maby-El Hajjami H., Cagnon L., Braun M., Derré L., Rivals J.-P., Rimoldi D., Gnjatic S. et al., 2016/10/02. OncoImmunology, 5 (10) pp. e1216290.
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
Murone M., Vaslin Chessex A., Attinger A., Ramachandra R., Shetty S.J., Daginakatte G., Sengupta S., Marappan S., Dhodheri S., Rigotti S. et al., 2016/10. Molecular cancer therapeutics, 15 (10) pp. 2334-2343. Peer-reviewed.
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Dittrich Christian, Kosty Michael, Jezdic Svetlana, Pyle Doug, Berardi Rossana, Bergh Jonas, El-Saghir Nagi, Lotz Jean-Pierre, Österlund Pia, Pavlidis Nicholas et al., 2016/09. ESMO Open, 1 (5) pp. e000097. Peer-reviewed.
Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.
Hoeller C., Michielin O., Ascierto P.A., Szabo Z., Blank C.U., 2016/09. Cancer immunology, immunotherapy : CII, 65 (9) pp. 1015-1034. Peer-reviewed.
SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening.
Zoete V., Daina A., Bovigny C., Michielin O., 2016/08/22. Journal of chemical information and modeling, 56 (8) pp. 1399-1404. Peer-reviewed.
Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.
Vallois D., Dobay M.P., Morin R.D., Lemonnier F., Missiaglia E., Juilland M., Iwaszkiewicz J., Fataccioli V., Bisig B., Roberti A. et al., 2016. Blood, 128 (11) pp. 1490-1502.
Attracting cavities for docking. Replacing the rough energy landscape of the protein by a smooth attracting landscape.
Zoete V., Schuepbach T., Bovigny C., Chaskar P., Daina A., Röhrig U.F., Michielin O., 2016. Journal of Computational Chemistry, 37 (4) pp. 437-447. Peer-reviewed.
Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.
Golay J., Choblet S., Iwaszkiewicz J., Cérutti P., Ozil A., Loisel S., Pugnière M., Ubiali G., Zoete V., Michielin O. et al., 2016. Journal of Immunology, 196 (7) pp. 3199-3211. Peer-reviewed.
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.
Bonilla X., Parmentier L., King B., Bezrukov F., Kaya G., Zoete V., Seplyarskiy V.B., Sharpe H.J., McKee T., Letourneau A. et al., 2016. Nature Genetics, 48 (4) pp. 398-406. Peer-reviewed.
In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by 19F-Fluorine MRS/MRI.
Gonzales C., Yoshihara H.A., Dilek N., Leignadier J., Irving M., Mieville P., Helm L., Michielin O., Schwitter J., 2016. PloS one, 11 (10) pp. e0164557. Peer-reviewed.
Principes de la thérapie cellulaire par transfert adoptif à base de Tumor Infiltrating Lymphocytes [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].
Martins F., Orcurto A., Michielin O., Coukos G., 2016. Revue Médicale Suisse, 12 (519) pp. 989-993. Peer-reviewed.
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
Dummer R., Siano M., Hunger R.E., Lindenblatt N., Braun R., Michielin O., Mihic-Probst D., von Moos R., Najafi Y., Guckenberger M. et al., 2016. Swiss Medical Weekly, 146 pp. w14279. Peer-reviewed.
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope.
Baumgaertner P., Costa Nunes C., Cachot A., Maby-El Hajjami H., Cagnon L., Braun M., Derré L., Rivals J.P., Rimoldi D., Gnjatic S. et al., 2016. Oncoimmunology, 5 (10) pp. e1216290. Peer-reviewed.
Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients-Report of a Phase I/IIa Clinical Trial.
Legat A., Maby-El Hajjami H., Baumgaertner P., Cagnon L., Abed Maillard S., Geldhof C., Iancu E.M., Lebon L., Guillaume P., Dojcinovic D. et al., 2016. Clinical Cancer Research, 22 (6) pp. 1330-1340. Peer-reviewed.
Michielin Olivier, Coukos George, 2015/09/09. Progress in Tumor Research, 42, S. Karger AG.
Nouvelles immunotherapies du mélanome: mécanismes d'action, efficacité et prise en charge des toxicities [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]
Moura B., Homicsko K., Berthod G., Cerottini J.P., Guggisberg D., Gaide O., Maillard M.H., Michielin O., 2015/05/20. Revue medicale suisse, 11 (475) pp. 1108,1110-1114.
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Mangana J., Cheng P.F., Schindler K., Weide B., Held U., Frauchiger A.L., Romano E., Kähler K.C., Rozati S., Rechsteiner M. et al., 2015. Plos One, 10 (10) pp. e0139438. Peer-reviewed.
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig U.F., Majjigapu S.R., Vogel P., Zoete V., Michielin O., 2015. Journal of Medicinal Chemistry, 58 (24) pp. 9421-9437. Peer-reviewed.
Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Michielin O., Hoeller C., 2015. Cancer Treatment Reviews, 41 (8) pp. 660-670. Peer-reviewed.
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Romano E., Kusio-Kobialka M., Foukas P.G., Baumgaertner P., Meyer C., Ballabeni P., Michielin O., Weide B., Romero P., Speiser D.E., 2015. Proceedings of the National Academy of Sciences of the United States of America, 112 (19) pp. 6140-6145.
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O., De Gassart A., Coso S., Gestermann N., Di Domizio J., Flatz L., Gaide O., Michielin O., Hwu P., Petrova T.V. et al., 2015. Proceedings of the National Academy of Sciences of the United States of America, 112 (50) pp. 15408-15413.
A WXW Motif Is Required for the Anticancer Activity of the TAT-RasGAP317-326 Peptide.
Barras D., Chevalier N., Zoete V., Dempsey R., Lapouge K., Olayioye M.A., Michielin O., Widmann C., 2014. Journal of Biological Chemistry, 289 (34) pp. 23701-23711.
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Kvistborg P., Philips D., Kelderman S., Hageman L., Ottensmeier C., Joseph-Pietras D., Welters M.J., van der Burg S., Kapiteijn E., Michielin O. et al., 2014. Science Translational Medicine, 6 (254) pp. 254ra128. Peer-reviewed.
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Röhrig U.F., Majjigapu S.R., Chambon M., Bron S., Pilotte L., Colau D., Van den Eynde B.J., Turcatti G., Vogel P., Zoete V. et al., 2014. European Journal of Medicinal Chemistry, 84 pp. 284-301.
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S., Bouchaab H., Zimmerman S., Bucher M., Gaide O., Letovanec I., Homicsko K., Michielin O., 2014. Melanoma Research, 24 (5) pp. 496-500.
Ensemble vers l'oncologie de précision [Together, towards precise oncology!].
Coukos G., Michielin O., Dietrich P., Aapro M., 2014. Revue Médicale Suisse, 10 (431) pp. 1099-1100.
Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support.
Stockinger H., Altenhoff A.M., Arnold K., Bairoch A., Bastian F., Bergmann S., Bougueleret L., Bucher P., Delorenzi M., Lane L. et al., 2014. Nucleic Acids Research, 42 (Web Server issue) pp. W436-W441. Peer-reviewed.
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Meyer C., Cagnon L., Costa-Nunes C.M., Baumgaertner P., Montandon N., Leyvraz L., Michielin O., Romano E., Speiser D.E., 2014. Cancer Immunology, Immunotherapy : Cii, 63 (3) pp. 247-257. Peer-reviewed.
iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach.
Daina A., Michielin O., Zoete V., 2014. Journal of Chemical Information and Modeling, 54 (12) pp. 3284-3301.
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
Romano E., Michielin O., Voelter V., Laurent J., Bichat H., Stravodimou A., Romero P., Speiser D.E., Triebel F., Leyvraz S. et al., 2014. Journal of Translational Medicine, 12 p. 97.
Médecine génomique et oncologie [Genomics medicine and oncology].
Michielin O., Coukos G., 2014. Praxis, 103 (10) pp. 591-596.
Pulmonary Sarcoid-like Granulomatosis after Multiple Vaccinations of a Long-term Surviving Patient with Metastatic Melanoma.
Bordry N., Costa-Nunes C.M., Cagnon L., Gannon P.O., Abed-Maillard S., Baumgaertner P., Murray T., Letovanec I., Lazor R., Bouchaab H. et al., 2014. Cancer Immunology Research, 2 (12) pp. 1148-1153.
Successes and Limitations of Targeted Cancer Therapy in Melanoma
Peters Solange, Stahel RA (eds.)Romano Emanuela, Michielin Olivier, 2014. Progress in Tumor Research, 41, S. KARGER AG.
Successes and limitations of targeted cancer therapy in melanoma.
Romano E., Michielin O., 2014. Progress in Tumor Research, 41 pp. 78-88. Peer-reviewed.
SwissTargetPrediction: a web server for target prediction of bioactive small molecules.
Gfeller D., Grosdidier A., Wirth M., Daina A., Michielin O., Zoete V., 2014. Nucleic Acids Research, 42 (W1) pp. W32-W38.
The caveolin-binding motif of the pathogen-related yeast protein Pry1, a member of the CAP protein superfamily, is required for in vivo export of cholesteryl acetate.
Choudhary V., Darwiche R., Gfeller D., Zoete V., Michielin O., Schneiter R., 2014. Journal of Lipid Research, 55 (5) pp. 883-894. Peer-reviewed.
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R., Goldinger S.M., Turtschi C.P., Eggmann N.B., Michielin O., Mitchell L., Veronese L., Hilfiker P.R., Felderer L., Rinderknecht J.D., 2014. European Journal of Cancer, 50 (3) pp. 611-621. Peer-reviewed.
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
Demierre N., Zoete V., Michielin O., Stauffer E., Zimmermann D.R., Betticher D.C., Peters S., 2013. Lung Cancer, 80 (1) pp. 81-84.
Axillary Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma Patients after Previous Axillary Surgery: A Systematic Review
Matter M., Romy S., Boubaker A., Michielin O., Demartines N., 2013. Journal of Cancer Therapy, 4 (9) pp. 1395-1402.
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.
Peters S., Michielin O., Zimmermann S., 2013. Journal of Clinical Oncology, 31 (20) pp. e341-e344.
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression.
Romano E., Pradervand S., Paillusson A., Weber J., Harshman K., Muehlethaler K., Speiser D., Peters S., Rimoldi D., Michielin O., 2013. Clinical Cancer Research, 19 (20) pp. 5749-5757.
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
Gautschi O., Peters S., Zoete V., Aebersold-Keller F., Strobel K., Schwizer B., Hirschmann A., Michielin O., Diebold J., 2013. Lung Cancer, 82 (2) pp. 365-367.
Nouvelles armes thérapeutiques contre le mélanome de stade IV [New therapeutic weapons in stage IV melanoma].
Tzika E., Moura B., Romano E., Michielin O., 2013. Revue Médicale Suisse, 9 (387) pp. 1095-1098.
Persistence of EBV Antigen-Specific CD8 T Cell Clonotypes during Homeostatic Immune Reconstitution in Cancer Patients.
Iancu E.M., Gannon P.O., Laurent J., Gupta B., Romero P., Michielin O., Romano E., Speiser D.E., Rufer N., 2013. Plos One, 8 (10) pp. e78686.
Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships.
Fagerberg T., Zoete V., Viatte S., Baumgaertner P., Alves P.M., Romero P., Speiser D.E., Michielin O., 2013. PLoS One, 8 (7) pp. e65590.
Protein pocket and ligand shape comparison and its application in virtual screening.
Wirth M., Volkamer A., Zoete V., Rippmann F., Michielin O., Rarey M., Sauer W.H., 2013. Journal of Computer-aided Molecular Design, 27 (6) pp. 511-524.
RNA pentaloop structures as effective targets of regulators belonging to the RsmA/CsrA protein family.
Lapouge K., Perozzo R., Iwaszkiewicz J., Bertelli C., Zoete V., Michielin O., Scapozza L., Haas D., 2013. RNA Biology, 10 (6) pp. 1031-1041. Peer-reviewed.
Shaping the interaction landscape of bioactive molecules.
Gfeller D., Michielin O., Zoete V., 2013. Bioinformatics, 29 (23) pp. 3073-3079.
SHP-1 phosphatase activity counteracts increased T cell receptor affinity.
Hebeisen M., Baitsch L., Presotto D., Baumgaertner P., Romero P., Michielin O., Speiser D.E., Rufer N., 2013. Journal of Clinical Investigation, 123 (3) pp. 1044-1056.
Structure-Based, Rational Design of T Cell Receptors.
Zoete V., Irving M., Ferber M., Cuendet M.A., Michielin O., 2013. Frontiers in Immunology, 4 p. 268.
SwissBioisostere: a database of molecular replacements for ligand design.
Wirth M., Zoete V., Michielin O., Sauer W.H., 2013. Nucleic Acids Research, 41 (D1) pp. D1137-D1143.
SwissSidechain: a molecular and structural database of non-natural sidechains.
Gfeller D., Michielin O., Zoete V., 2013. Nucleic Acids Research, 41 (D1) pp. D327-D332. Peer-reviewed.
The Peroxisomal Enzyme L-PBE Is Required to Prevent the Dietary Toxicity of Medium-Chain Fatty Acids.
Ding J., Loizides-Mangold U., Rando G., Zoete V., Michielin O., Reddy J.K., Wahli W., Riezman H., Thorens B., 2013. Cell Reports, 5 (1) pp. 248-258.
Defining and searching for structural motifs using DeepView/Swiss-PdbViewer.
Johansson M.U., Zoete V., Michielin O., Guex N., 2012. BMC Bioinformatics, 13 p. 173. Peer-reviewed.
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
Nikolaev S.I., Rimoldi D., Iseli C., Valsesia A., Robyr D., Gehrig C., Harshman K., Guipponi M., Bukach O., Zoete V. et al., 2012. Nature Genetics, 44 (2) pp. 133-139.
Expanding molecular modeling and design tools to non-natural sidechains.
Gfeller D., Michielin O., Zoete V., 2012. Journal of Computational Chemistry, 33 (18) pp. 1525-1535.
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.
Baitsch L., Legat A., Barba L., Fuertes Marraco S.A., Rivals J.P., Baumgaertner P., Christiansen-Jucht C., Bouzourene H., Rimoldi D., Pircher H. et al., 2012. PLoS One, 7 (2) pp. e30852.
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
von Moos R., Seifert B., Simcock M., Goldinger S.M., Gillessen S., Ochsenbein A., Michielin O., Cathomas R., Schläppi M., Moch H. et al., 2012. Annals of Oncology, 23 (2) pp. 531-6.
Human CD8(+) T cells engineered with supraphysiological TCRs are functionally inhibited via PD-1 and SHP-1 phosphatase
Hebeisen M., Baitsch L., Presotto D., Baumgaertner P., Romero P., Michielin O., Speiser D. E., Rufer N., 2012. p. 713 dans European Congress of Immunology, Immunology.
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.
Irving M., Zoete V., Hebeisen M., Schmid D., Baumgartner P., Guillaume P., Romero P., Speiser D., Luescher I., Rufer N. et al., 2012. Journal of Biological Chemistry, 287 (27) pp. 23068-23078. Peer-reviewed.
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Goldinger S.M., Dummer R., Baumgaertner P., Mihic-Probst D., Schwarz K., Hammann-Haenni A., Willers J., Geldhof C., Prior J.O., Kündig T.M. et al., 2012. European Journal of Immunology, 42 (11) pp. 3049-3061.
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Schraml P., von Teichman A., Mihic-Probst D., Simcock M., Ochsenbein A., Dummer R., Michielin O., Seifert B., Schläppi M., Moch H. et al., 2012. Oncology Reports, 28 (2) pp. 654-658.
Pulmonary sarcoid-like granulomatosis induced by ipilimumab.
Berthod G., Lazor R., Letovanec I., Romano E., Noirez L., Mazza Stalder J., Speiser D.E., Peters S., Michielin O., 2012. Journal of Clinical Oncology, 30 (17) pp. e156-e159.
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.
Röhrig U.F., Majjigapu S.R., Grosdidier A., Bron S., Stroobant V., Pilotte L., Colau D., Vogel P., Van den Eynde B.J., Zoete V. et al., 2012. Journal of Medicinal Chemistry, 55 (11) pp. 5270-5290. Peer-reviewed.
Recommandations pour la prise en charge du mélanome
Bron L., Cerottini J.P., Dietrich P.Y., Gugerli O., Guggisberg D., Legal F.A., Matter M., Matzinger O., Michielin O., Voelte V., 2012., 3e édition [44], Groupe Mélanome Lémanique.
Sequence determinants of a microtubule tip localization signal (MtLS).
Buey R.M., Sen I., Kortt O., Mohan R., Gfeller D., Veprintsev D., Kretzschmar I., Scheuermann J., Neri D., Zoete V. et al., 2012. Journal of Biological Chemistry, 287 (34) pp. 28227-28242. Peer-reviewed.
T-Cell Receptors Binding Orientation over Peptide/MHC Class I Is Driven by Long-Range Interactions.
Ferber M., Zoete V., Michielin O., 2012. PLoS One, 7 (12) pp. e51943.
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells.
Baumgaertner P., Jandus C., Rivals J.P., Derré L., Lövgren T., Baitsch L., Guillaume P., Luescher I.F., Berthod G., Matter M. et al., 2012. International Journal of Cancer. Journal International Du Cancer, 130 (11) pp. 2607-2617.
Fast docking using the CHARMM force field with EADock DSS.
Grosdidier A., Zoete V., Michielin O., 2011. Journal of Computational Chemistry, 32 (10) pp. 2149-2159.
Homology-based identification of capsid determinants that protect HIV1 from human TRIM5{alpha} restriction.
Maillard P.V., Zoete V., Michielin O., Trono D., 2011. Journal of Biological Chemistry, 286 (10) pp. 8128-8140.
How T cell receptors interact with peptide-MHCs: A multiple steered molecular dynamics study.
Cuendet M.A., Zoete V., Michielin O., 2011. Proteins, 79 (11) pp. 3007-3024.
Identification of human IKK-2 inhibitors of natural origin (part I): modeling of the IKK-2 kinase domain, virtual screening and activity assays.
Sala E., Guasch L., Iwaszkiewicz J., Mulero M., Salvadó M.J., Pinent M., Zoete V., Grosdidier A., Garcia-Vallvé S., Michielin O. et al., 2011. Plos One, 6 (2) pp. e16903.
Identification of human IKK-2 inhibitors of natural origin (Part II): in Silico prediction of IKK-2 inhibitors in natural extracts with known anti-inflammatory activity.
Sala E., Guasch L., Iwaszkiewicz J., Mulero M., Salvadó M.J., Bladé C., Ceballos M., Valls C., Zoete V., Grosdidier A. et al., 2011. European Journal of Medicinal Chemistry, 46 (12) pp. 6098-6103.
Mélanome: une nouvette ère thérapeutique [Melanoma: a new therapeutic era].
Berthod G., Homicsko K., Bouchaab H., Matter M., Cerottini J.P., Guggisberg D., Speiser D., Leyvraz S., Michielin O., 2011. Revue Médicale Suisse, 7 (296) pp. 1126-1130.
Optimal CD8 T cell responsiveness is controlled within a defined TCR affinity window
Hebeisen M., Irving M., Schmid D., Zoete V., Romero P., Speiser D., Michielin O., Rufer N., 2011. p. 111 dans Annual Congress SGAI-SSAI, Advances in immunology and allergology: from research to diagnosis and therapy, Allergologie. Peer-reviewed.
Sentinel nodes and and non sentinel nodes evaluation in T1 melanoma patients
Matter M., Boubaker A., Michielin O., Demartines N., 2011. pp. 7-8 dans 98th Annual Congress of the Swiss Society of Surgery, British Journal of Surgery. Peer-reviewed.
Single cell analysis reveals similar functional competence of dominant and non-dominant CD8 T-cell clonotypes
Rufer N., Wieckowski S., Gupta B., Iancu E., Baumgaertner P., Michielin O., Romero P., Speiser D., 2011. p. 108 dans Annual Congress SGAI-SSAI, Advances in immunology and allergology: from research to diagnosis and therapy, Allergologie. Peer-reviewed.
Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes.
Speiser D.E., Wieckowski S., Gupta B., Iancu E.M., Baumgaertner P., Baitsch L., Michielin O., Romero P., Rufer N., 2011. Proceedings of the National Academy of Sciences of the United States of America, 108 (37) pp. 15318-15323.
Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities.
Bulliard Y., Narvaiza I., Bertero A., Peddi S., Röhrig U.F., Ortiz M., Zoete V., Castro-Díaz N., Turelli P., Telenti A. et al., 2011. Journal of Virology, 85 (4) pp. 1765-1776.
SwissDock, a protein-small molecule docking web service based on EADock DSS.
Grosdidier A., Zoete V., Michielin O., 2011. Nucleic Acids Research, 39 (Suppl. 2) pp. W270-W277.
SwissParam: a fast force field generation tool for small organic molecules.
Zoete V., Cuendet M.A., Grosdidier A., Michielin O., 2011. Journal of Computational Chemistry, 32 (11) pp. 2359-2368.
TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires.
Leimgruber A., Ferber M., Irving M., Hussain-Kahn H., Wieckowski S., Derré L., Rufer N., Zoete V., Michielin O., 2011. PLoS One, 6 (10) pp. e26301.
The V-ATPase proteolipid cylinder promotes the lipid-mixing stage of SNARE-dependent fusion of yeast vacuoles.
Strasser B., Iwaszkiewicz J., Michielin O., Mayer A., 2011. EMBO Journal, 30 (20) pp. 4126-4141.
Unique spectrum of activity of prosimian TRIM5alpha against exogenous and endogenous retroviruses.
Rahm N., Yap M., Snoeck J., Zoete V., Muñoz M., Radespiel U., Zimmermann E., Michielin O., Stoye J.P., Ciuffi A. et al., 2011. Journal of Virology, 85 (9) pp. 4173-4183.
A combined computational and functional approach identifies new residues involved in pH-dependent gating of ASIC1a.
Liechti L.A., Bernèche S., Bargeton B., Iwaszkiewicz J., Roy S., Michielin O., Kellenberger S., 2010. Journal of Biological Chemistry, 285 (21) pp. 16315-16329.
A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to Streptococcus gordonii.
Bizzini A., Entenza J.M., Michielin O., Arnold I., Erni B., Moreillon P., 2010. Antimicrobial Agents and Chemotherapy, 54 (1) pp. 259-266.
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Derré L., Rivals J.P., Jandus C., Pastor S., Rimoldi D., Romero P., Michielin O., Olive D., Speiser D.E., 2010. Journal of Clinical Investigation, 120 (1) pp. 157-167.
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.
Schmid D.A., Irving M.B., Posevitz V., Hebeisen M., Posevitz-Fejfar A., Sarria J.C., Gomez-Eerland R., Thome M., Schumacher T.N., Romero P. et al., 2010. Journal of Immunology, 184 (9) pp. 4936-4946. Peer-reviewed.
Fourier transform convolution integrals applied to generalized Born molecular volume.
Schüpbach T., Zoete V., Tsakam-Sotché B., Michielin O., 2010. Journal of Computational Chemistry, 31 (3) pp. 649-659.
Frequent MAGE mutations in human melanoma.
Caballero O.L., Zhao Q., Rimoldi D., Stevenson B.J., Svobodová S., Devalle S., Röhrig U.F., Pagotto A., Michielin O., Speiser D. et al., 2010. PLoS One, 5 (9) pp. e12773.
MM-GBSA binding free energy decomposition and T cell receptor engineering.
Zoete V., Irving M.B., Michielin O., 2010. Journal of Molecular Recognition, 23 (2) pp. 142-152.
Rational design of indoleamine 2,3-dioxygenase inhibitors.
Röhrig U.F., Awad L., Grosdidier A., Larrieu P., Stroobant V., Colau D., Cerundolo V., Simpson A.J., Vogel P., Van den Eynde B.J. et al., 2010. Journal of Medicinal Chemistry, 53 (3) pp. 1172-1189.
Use of the FACTS solvation model for protein-ligand docking calculations. Application to EADock.
Zoete V., Grosdidier A., Cuendet M., Michielin O., 2010. Journal of Molecular Recognition, 23 (5) pp. 457-461.
Blind docking of 260 protein-ligand complexes with EADock 2.0.
Grosdidier A., Zoete V., Michielin O., 2009. Journal of Computational Chemistry, 30 (13) pp. 2021-2030.
Docking to heme proteins.
Röhrig U.F., Grosdidier A., Zoete V., Michielin O., 2009. Journal of Computational Chemistry, 30 (14) pp. 2305-2315.
Docking, virtual high throughput screening and in silico fragment-based drug design.
Zoete V., Grosdidier A., Michielin O., 2009. Journal of Cellular and Molecular Medicine, 13 (2) pp. 238-248. Peer-reviewed.
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior J.O., Montemurro M., Orcurto M.V., Michielin O., Luthi F., Benhattar J., Guillou L., Elsig V., Stupp R., Delaloye A.B. et al., 2009. Journal of Clinical Oncology, 27 (3) pp. 439-445. Peer-reviewed.
Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition.
Bulliard Y., Turelli P., Röhrig U.F., Zoete V., Mangeat B., Michielin O., Trono D., 2009. Journal of Virology, 83 (23) pp. 12611-12621.
Inhibition of the shade avoidance response by formation of non-DNA binding bHLH heterodimers.
Hornitschek P., Lorrain S., Zoete V., Michielin O., Fankhauser C., 2009. EMBO journal, 28 (24) pp. 3893-3902.
Molecular Modeling of Proteins: From Simulations to Drug Design Applications
Zoete V., Cuendet M, Röhrig U.F., Grosdidier A., Michielin O., 2009. pp. 247-281 dans Appel R.D., Feytmans E. (eds.) Bioinformatics: s swiss perspective, World Scientific.
Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)
Von Moos R., Seifert B., Ochsenbein A., Cathomas R., Schlaeppi M., Gillessen S., Schuller J.C., Michielin O., Goldinger S., Dummer R., 2009. pp. 13-14 dans 15th ECCO/34th ESMO Multidisciplinary Congress, Ejc Supplements. Peer-reviewed.
Molecular Dynamics-based Free Energy Simulations
Cuendet M. A., Zoete V., Michielin O., 2008/05., WORLD SCIENTIFIC.
Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor.
Voelter V., Rufer N., Reynard S., Greub G., Brookes R., Guillaume P., Grosjean F., Fagerberg T., Michielin O., Rowland-Jones S. et al., 2008. International Immunology, 20 (8) pp. 1087-1096. Peer-reviewed.
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues.
Derré L., Bruyninx M., Baumgaertner P., Ferber M., Schmid D., Leimgruber A., Zoete V., Romero P., Michielin O., Speiser D.E. et al., 2008. Proceedings of the National Academy of Sciences of the United States of America, 105 (39) pp. 15010-15015. Peer-reviewed.
In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1.
Rochat B., Zoete V., Grosdidier A., von Grünigen S., Marull M., Michielin O., 2008. Biopharmaceutics and drug disposition, 29 (2) pp. 103-118. Peer-reviewed.
Local alignment refinement using structural assessment.
Chodanowski P., Grosdidier A., Feytmans E., Michielin O., 2008. PLoS ONE, 3 (7) pp. e2645. Peer-reviewed.
Nouveautés dans l'immunothérapie du cancer [New developments in cancer immunotherapy]
Michielin O., Rufer N., Romero P., Laurent J., Cerottini J.P., Gugisberg D., Leyvraz S., Speiser D., 2008. Revue Médicale Suisse, 4 (158) pp. 1248-1251.
Protein-protein interaction investigated by steered molecular dynamics: the TCR-pMHC complex.
Cuendet M.A., Michielin O., 2008. Biophysical journal, 95 (8) pp. 3575-3590.
The fourth extracellular loop of the alpha subunit of Na,K-ATPase. Functional evidence for close proximity with the second extracellular loop.
Capendeguy O., Iwaszkiewicz J., Michielin O., Horisberger J.D., 2008. Journal of Biological Chemistry, 283 (41) pp. 27850-27858. Peer-reviewed.
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.
Derré L., Ferber M., Touvrey C., Devevre E., Zoete V., Leimgruber A., Romero P., Michielin O., Lévy F., Speiser D.E., 2007/12/01. Journal of immunology, 179 (11) pp. 7635-7645. Peer-reviewed.
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.
Derré L., Ferber M., Touvrey C., Devevre E., Zoete V., Leimgruber A., Romero P., Michielin O., Lévy F., Speiser D.E., 2007. Journal of Immunology, 179 (11) pp. 7635-7645.
Application de la modélisation moléculaire à de nouvelles approches thérapeutiques du cancer [Application of molecular modeling to new therapeutic cancer approaches].
Michielin O., 2007. Bulletin du Cancer, 94 (9) pp. 763-768.
Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior.
Michalik L., Zoete V., Krey G., Grosdidier A., Gelman L., Chodanowski P., Feige J.N., Desvergne B., Wahli W., Michielin O., 2007. Journal of Biological Chemistry, 282 (13) pp. 9666-9677. Peer-reviewed.
Comparison between computational alanine scanning and per-residue binding free energy decomposition for protein-protein association using MM-GBSA: application to the TCR-p-MHC complex.
Zoete V., Michielin O., 2007. Proteins, 67 (4) pp. 1026-1047.
EADock: docking of small molecules into protein active sites with a multiobjective evolutionary optimization.
Grosdidier A., Zoete V., Michielin O., 2007. Proteins, 67 (4) pp. 1010-1025.
Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
Alves P.M., Viatte S., Fagerberg T., Michielin O., Bricard G., Bouzourene H., Vuilleumier H., Kruger T., Givel J.C., Lévy F. et al., 2007. Cancer immunology, immunotherapy, 56 (11) pp. 1795-1805. Peer-reviewed.
Model structure of human APOBEC3G.
Zhang K.L., Mangeat B., Ortiz M., Zoete V., Trono D., Telenti A., Michielin O., 2007. PLoS ONE, 2 (4) pp. e378. Peer-reviewed.
Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators.
Zoete V., Grosdidier A., Michielin O., 2007. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, 1771 (8) pp. 915-925. Peer-reviewed.
Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation.
Butticaz C., Michielin O., Wyniger J., Telenti A., Rothenberger S., 2007. Journal of virology, 81 (3) pp. 1502150-5. Peer-reviewed.
The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis.
Feige J.N., Gelman L., Rossi D., Zoete V., Métivier R., Tudor C., Anghel S.I., Grosdidier A., Lathion C., Engelborghs Y. et al., 2007. Journal of Biological Chemistry, 282 (26) pp. 19152-19166. Peer-reviewed.
Un guide pratique au traitement des gliomes [A practical guide for the management of gliomas]
Stupp R., Pica A., Mirimanoff R.O., Michielin O., 2007. Bulletin du cancer, 94 (9) pp. 817-22.
A natural structural variant of the mouse TCR beta-chain displays intrinsic receptor function and antigen specificity.
Aublin A., Ciofani M., Willkomm N., Hamrouni A., Szymczak-Workman A.L., Takahashi T., Sandjeu Y., Guillaume P., Vignali D.A., Michielin O. et al., 2006. Journal of immunology, 177 (12) pp. 8587-8594. Peer-reviewed.
Access of extracellular cations to their binding sites in Na,K-ATPase: role of the second extracellular loop of the alpha subunit.
Capendeguy O., Chodanowski P., Michielin O., Horisberger J.D., 2006. The Journal of general physiology, 127 (3) pp. 341-s52. Peer-reviewed.
Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
Colombetti S., Fagerberg T., Baumgärtner P., Chapatte L., Speiser D.E., Rufer N., Michielin O., Lévy F., 2006. Journal of Immunology, 176 (11) pp. 6560-6567. Peer-reviewed.
Structural assessment of single amino acid mutations: application to TP53 function.
Yip Y.L., Zoete V., Scheib H., Michielin O., 2006. Human mutation, 27 (9) pp. 926-937.
Structural prediction of peptides bound to MHC class I.
Fagerberg T., Cerottini J.C., Michielin O., 2006. Journal of molecular biology, 356 (2) pp. 521-546. Peer-reviewed.
CD8+ cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers.
Cebecauer M., Guillaume P., Mark S., Michielin O., Boucheron N., Bezard M., Meyer B.H., Segura J.M., Vogel H., Luescher I.F., 2005. The Journal of biological chemistry, 280 (25) pp. 23820-23828. Peer-reviewed.
Chimioprévention actuelle et visions futures [Present chemoprevention and future vision].
Filges I., Zaman K., Michielin O., Vulliémoz D., Perey L., Stupp R., 2005. Revue Médicale Suisse, 1 (20) pp. 1343-6, 1349.
Functional dynamics of PDZ binding domains: a normal-mode analysis.
De Los Rios P., Cecconi F., Pretre A., Dietler G., Michielin O., Piazza F., Juanico B., 2005. Biophysical journal, 89 (1) pp. 14-21. Peer-reviewed.
Structure-function characterization and optimization of a plant-derived antibacterial peptide.
Suarez M., Haenni M., Canarelli S., Fisch F., Chodanowski P., Servis C., Michielin O., Freitag R., Moreillon P., Mermod N., 2005. Antimicrobial Agents and Chemotherapy, 49 (9) pp. 3847-3857.
Tinkering with nature: the tale of optimizing peptide based cancer vaccines.
Michielin O., Blanchet J.S., Fagerberg T., Valmori D., Rubio-Godoy V., Speiser D., Ayyoub M., Alves P., Luescher I., Gairin J.E. et al., 2005. Cancer treatment and research, 123 pp. 267-291.
A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation.
Hauert J., Fernandez-Carneado J., Michielin O., Mathieu S., Grell D., Schapira M., Spertini O., Mutter M., Tuchscherer G., Kovacsovics T., 2004. Chembiochem, 5 (6) pp. 856-864. Peer-reviewed.
Irinotecan-induced interstitial pneumonia.
Michielin O., Udry E., Périard D., Matzinger O., Lobrinus J.A., Stupp R., 2004. Lancet Oncology, 5 (5) pp. 322-324. Peer-reviewed.
Structural and functional interaction sites between Na,K-ATPase and FXYD proteins.
Li C., Grosdidier A., Crambert G., Horisberger J.D., Michielin O., Geering K., 2004. The Journal of biological chemistry, 279 (37) pp. 38895-902. Peer-reviewed.
The fourth transmembrane segment of the Na,K-ATPase alpha subunit: a systematic mutagenesis study.
Horisberger J.D., Kharoubi-Hess S., Guennoun S., Michielin O., 2004. The Journal of biological chemistry, 279 (28) pp. 29542-50. Peer-reviewed.
Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1.
Schwitzgebel V.M., Mamin A., Brun T., Ritz-Laser B., Zaiko M., Maret A., Jornayvaz F.R., Theintz G.E., Michielin O., Melloul D. et al., 2003. The Journal of clinical endocrinology and metabolism, 88 (9) pp. 4398-406. Peer-reviewed.
CD3 delta establishes a functional link between the T cell receptor and CD8.
Doucey M.A., Goffin L., Naeher D., Michielin O., Baumgärtner P., Guillaume P., Palmer E., Luescher I.F., 2003. Journal of Biological Chemistry, 278 (5) pp. 3257-3264. Peer-reviewed.
Molecular basis of leukocyte rolling on PSGL-1. Predominant role of core-2 O-glycans and of tyrosine sulfate residue 51.
Bernimoulin M.P., Zeng X.L., Abbal C., Giraud S., Martinez M., Michielin O., Schapira M., Spertini O., 2003. The Journal of biological chemistry, 278 (1) pp. 37-47. Peer-reviewed.
Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
Dietrich P.Y., Le Gal F.A., Dutoit V., Pittet M.J., Trautman L., Zippelius A., Cognet I., Widmer V., Walker P.R., Michielin O. et al., 2003. Journal of Immunology, 170 (10) pp. 5103-5109.
Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors.
Zoete V., Michielin O., Karplus M., 2003. Journal of computer-aided molecular design, 17 (12) pp. 861-880. Peer-reviewed.
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
Romero P., Valmori D., Pittet M.J., Zippelius A., Rimoldi D., Lévy F., Dutoit V., Ayyoub M., Rubio-Godoy V., Michielin O. et al., 2002. Immunological reviews, 188 pp. 81-96. Peer-reviewed.
Binding free energy differences in a TCR-peptide-MHC complex induced by a peptide mutation: a simulation analysis.
Michielin O., Karplus M., 2002. Journal of molecular biology, 324 (3) pp. 547-569. Peer-reviewed.
Conformational analysis of a stereochemically complete set of cis-enediol peptide analogues.
Michielin O., Zoete V., Gierasch T.M., Eckstein J., Napper A., Verdine G., Karplus M., 2002. Journal of the American Chemical Society, 124 (37) pp. 11131-11141. Peer-reviewed.
Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility.
Zoete V., Michielin O., Karplus M., 2002. Journal of molecular biology, 315 (1) pp. 21-52. Peer-reviewed.
Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes.
Sliz P., Michielin O., Cerottini J.C., Luescher I., Romero P., Karplus M., Wiley D.C., 2001. Journal of immunology, 167 (6) pp. 3276-3284. Peer-reviewed.
Unicentre - CH-1015 Lausanne
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University